Matthew J Glasgow1, Jane E Harding2, Richard Edlin3. 1. Liggins Institute, University of Auckland, Auckland, New Zealand. 2. Liggins Institute, University of Auckland, Auckland, New Zealand. Electronic address: j.harding@auckland.ac.nz. 3. Department of Health Systems, University of Auckland, Auckland, New Zealand.
Abstract
OBJECTIVE: To evaluate the costs of using dextrose gel as a primary treatment for neonatal hypoglycemia in the first 48 hours after birth compared with standard care. STUDY DESIGN: We used a decision tree to model overall costs, including those specific to hypoglycemia monitoring and treatment and those related to the infant's length of stay in the postnatal ward or neonatal intensive care unit, comparing the use of dextrose gel for treatment of neonatal hypoglycemia with placebo, using data from the Sugar Babies randomized trial. Sensitivity analyses assessed the impact of dextrose gel cost, neonatal intensive care cost, cesarean delivery rate, and costs of glucose monitoring. RESULTS: In the primary analysis, treating neonatal hypoglycemia using dextrose gel had an overall cost of NZ$6863.81 and standard care (placebo) cost NZ$8178.25; a saving of NZ$1314.44 per infant treated. Sensitivity analyses showed that dextrose gel remained cost saving with wide variations in dextrose gel costs, neonatal intensive care unit costs, cesarean delivery rates, and costs of monitoring. CONCLUSIONS: Use of buccal dextrose gel reduces hospital costs for management of neonatal hypoglycemia. Because it is also noninvasive, well tolerated, safe, and associated with improved breastfeeding, buccal dextrose gel should be routinely used for initial treatment of neonatal hypoglycemia. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12608000623392.
OBJECTIVE: To evaluate the costs of using dextrose gel as a primary treatment for neonatal hypoglycemia in the first 48 hours after birth compared with standard care. STUDY DESIGN: We used a decision tree to model overall costs, including those specific to hypoglycemia monitoring and treatment and those related to the infant's length of stay in the postnatal ward or neonatal intensive care unit, comparing the use of dextrose gel for treatment of neonatal hypoglycemia with placebo, using data from the Sugar Babies randomized trial. Sensitivity analyses assessed the impact of dextrose gel cost, neonatal intensive care cost, cesarean delivery rate, and costs of glucose monitoring. RESULTS: In the primary analysis, treating neonatal hypoglycemia using dextrose gel had an overall cost of NZ$6863.81 and standard care (placebo) cost NZ$8178.25; a saving of NZ$1314.44 per infant treated. Sensitivity analyses showed that dextrose gel remained cost saving with wide variations in dextrose gel costs, neonatal intensive care unit costs, cesarean delivery rates, and costs of monitoring. CONCLUSIONS: Use of buccal dextrose gel reduces hospital costs for management of neonatal hypoglycemia. Because it is also noninvasive, well tolerated, safe, and associated with improved breastfeeding, buccal dextrose gel should be routinely used for initial treatment of neonatal hypoglycemia. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12608000623392.
Authors: Christopher J D McKinlay; Jane M Alsweiler; Judith M Ansell; Nicola S Anstice; J Geoffrey Chase; Gregory D Gamble; Deborah L Harris; Robert J Jacobs; Yannan Jiang; Nabin Paudel; Matthew Signal; Benjamin Thompson; Trecia A Wouldes; Tzu-Ying Yu; Jane E Harding Journal: N Engl J Med Date: 2015-10-15 Impact factor: 91.245
Authors: Jeffrey R Kaiser; Shasha Bai; Neal Gibson; Greg Holland; Tsai Mei Lin; Christopher J Swearingen; Jennifer K Mehl; Nahed O ElHassan Journal: JAMA Pediatr Date: 2015-10 Impact factor: 16.193
Authors: Taygen Edwards; Gordon Liu; Malcolm Battin; Deborah L Harris; Joanne E Hegarty; Philip J Weston; Jane E Harding Journal: Cochrane Database Syst Rev Date: 2022-03-18
Authors: Marina S Oren; Whittney D Barkhuff; Andrei Stefanescu; Beatrice M Stefanescu; Tara L DuPont Journal: J Perinatol Date: 2020-09-22 Impact factor: 2.521
Authors: Taygen Edwards; Gordon Liu; Joanne E Hegarty; Caroline A Crowther; Jane Alsweiler; Jane E Harding Journal: Cochrane Database Syst Rev Date: 2021-05-17
Authors: Don Laing; Eamon Walsh; Jane M Alsweiler; Sara M Hanning; Michael P Meyer; Julena Ardern; Wayne S Cutfield; Jenny Rogers; Greg D Gamble; J Geoffrey Chase; Jane E Harding; Christopher Jd McKinlay Journal: BMJ Open Date: 2022-08-17 Impact factor: 3.006